Metsera Inc., a clinical-stage biopharmaceutical company, has announced progress in its ongoing clinical programs targeting obesity and metabolic diseases. The company is advancing its MET-097i program, a fully biased, monthly injectable GLP-1 receptor agonist, with the release of VESPER-1 and interim VESPER-3 data anticipated in September 2025. These results will contribute to the development of Phase 3 trials slated for late 2025. Additionally, Metsera's MET-233i, a once-monthly amylin analog, has shown promising Phase 1 results with an 8.4% weight loss over five weeks and a 19-day half-life. Further 12-week monotherapy and co-administration data are expected by the end of 2025 or early 2026. Metsera's pipeline also includes oral peptide programs, with four-week data for selected leads expected in late 2025. The company maintains a robust financial position, with $530.9 million in cash and cash equivalents, ensuring operational runway into 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.